Ampio Pharmaceuticals (NYSE:AMPE) vs. ProMetic Life Sciences (OTCMKTS:PFSCF) Financial Review

Insider & Institutional Ownership

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of ProMetic Life Sciences shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Ampio Pharmaceuticals and ProMetic Life Sciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63 million	($11.01)	-0.02
ProMetic Life Sciences	$36.55 million	3.49	-$150.73 million	N/A	N/A

Ampio Pharmaceuticals has higher earnings, but lower revenue than ProMetic Life Sciences.

Profitability

This table compares Ampio Pharmaceuticals and ProMetic Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
ProMetic Life Sciences	-894.02%	-3,350.55%	-67.76%

Volatility and Risk

Ampio Pharmaceuticals has a beta of 5.96, suggesting that its share price is 496% more volatile than the S&P 500. Comparatively, ProMetic Life Sciences has a beta of 2.46, suggesting that its share price is 146% more volatile than the S&P 500.

Summary

Ampio Pharmaceuticals beats ProMetic Life Sciences on 7 of the 8 factors compared between the two stocks.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

About ProMetic Life Sciences

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.